Mesoblast Limited (MEOBF)

Market Cap	2.08B +11.5%
Revenue (ttm)	120.25M +599.2%
Net Income	-57.50M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250
Open	1.900
Previous Close	1.650
Day's Range	1.900 - 1.900
52-Week Range	1.300 - 2.590
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Mesoblast

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative coli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 108
• Stock Exchange: OTCMKTS
• Ticker Symbol: MEOBF

Financial Performance

In fiscal year 2026, Mesoblast's revenue was $120.25 million, an increase of 599.21% compared to the previous year's $17.20 million. Losses were -$57.50 million, -43.71% less than in 2025.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 9, 2026

Data Sources Report a data error